Ovid Therapeutics Inc (NASDAQ:OVID) price on Thursday, July 24, fall -1.00% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.69.
A look at the stock’s price movement, the close in the last trading session was $0.7, moving within a range at $0.6011 and $0.7275. The beta value (5-Year monthly) was 0.131. Turning to its 52-week performance, $1.47 and $0.24 were the 52-week high and 52-week low respectively. Overall, OVID moved 129.70% over the past month.
Ovid Therapeutics Inc’s market cap currently stands at around $49.28 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Jun-06.
The average forecast suggests down to a -44.87% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 322.86k, representing a -42.96% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that OVID is a 50% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 4 recommend OVID as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
OVID’s current price about 56.14% and 94.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 81.50, while 7-day volatility ratio is 14.48% and 13.32% in the 30-day chart. Further, Ovid Therapeutics Inc (OVID) has a beta value of 0.28. Analysts have given the company’s stock an average 52-week price target of $8, forecast between a low of $3 and high of $11. Looking at the price targets, the low is -334.78% off current price level while to achieve the yearly target high, price needs to move -1494.2%. Nonetheless, investors will most likely welcome a -1059.42% jump to $8 which is the analysts’ median price.
If we refocus on Ovid Therapeutics Inc (NASDAQ:OVID), historical trading data shows that trading volumes averaged 3.91 over the past 10 days and 1.46 million over the past 3 months. The company’s latest data on shares outstanding shows there are 71.11 million shares.
The 16.32% of Ovid Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 42.86% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.24 million on 2025-06-30, giving us a short ratio of 0.75. The data shows that as of 2025-06-30 short interest in Ovid Therapeutics Inc (OVID) stood at 208.0 of shares outstanding, with shares short falling to 1.66 million registered in 2025-05-30. Current price change has pushed the stock -32.72% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the OVID stock continues to rise going into the next quarter.
